Abbott Laboratories (ABT) : R. G. Niederhoffer Capital Management Inc added new position in Abbott Laboratories during the most recent quarter end. The investment management firm now holds 4,800 shares of Abbott Laboratories which is valued at $188,160 , the company said in a statement filed on Nov 14, 2016 with the SEC.Abbott Laboratories makes up approximately 0.88% of R. G. Niederhoffer Capital Management Inc’s portfolio.
Other Hedge Funds, Including , Horizon Investments reduced its stake in ABT by selling 68,267 shares or 79.78% in the most recent quarter. The Hedge Fund company now holds 17,307 shares of ABT which is valued at $678,434. Abbott Laboratories makes up approx 0.05% of Horizon Investments’s portfolio.Guardian Investment Management boosted its stake in ABT in the latest quarter, The investment management firm added 600 additional shares and now holds a total of 32,066 shares of Abbott Laboratories which is valued at $1,278,151. Abbott Laboratories makes up approx 1.54% of Guardian Investment Management’s portfolio.Northstar Investment Advisors boosted its stake in ABT in the latest quarter, The investment management firm added 17,950 additional shares and now holds a total of 171,768 shares of Abbott Laboratories which is valued at $6,740,176. Abbott Laboratories makes up approx 1.56% of Northstar Investment Advisors’s portfolio.Livingston Group Asset Management Co (operating As Southp… reduced its stake in ABT by selling 946 shares or 13.98% in the most recent quarter. The Hedge Fund company now holds 5,821 shares of ABT which is valued at $239,651. Abbott Laboratories makes up approx 0.17% of Livingston Group Asset Management Co (operating As Southp…’s portfolio.
Abbott Laboratories closed down -0.55 points or -1.36% at $39.84 with 70,15,102 shares getting traded on Monday. Post opening the session at $40.31, the shares hit an intraday low of $39.8 and an intraday high of $40.42 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Abbott Laboratories reported $0.59 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Oct 19, 2016. Analyst had a consensus of $0.58. The company had revenue of $5302.00 million for the quarter, compared to analysts expectations of $5288.92 million. The company’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.